Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694262 · ClinicalTrials.gov registry record · Phase 2
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
A Phase 2 study of Endometrial Cancer and Uterine Carcinosarcoma, sponsored by Medical College of Wisconsin.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT03694262 is a Phase 2 study of Endometrial Cancer and Uterine Carcinosarcoma that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 30 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03694262, a Phase 2 study of Endometrial Cancer and Uterine Carcinosarcoma, is active but no longer recruiting, sponsored by Medical College of Wisconsin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Rucaparib
Study Locations (3)
New York
- Mount Sinai - New York
Pennsylvania
- St. Luke's Hospital and Health Network - Bethlehem
Wisconsin
- Froedtert Lutheran Memorial Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-07-19 |
| Est. Completion | 2026-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694262
The ClinicalTrials.gov registry entry for NCT03694262 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT03694262 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Pennsylvania, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03694262 about?
NCT03694262 is a clinical study titled "The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)". To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.
What is the current status of trial NCT03694262?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-07-19. Estimated completion is 2026-01-05.
What conditions does trial NCT03694262 study?
This clinical trial studies the following conditions: Endometrial Cancer, Uterine Carcinosarcoma.
What interventions are being tested in trial NCT03694262?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03694262?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03694262 being conducted?
This trial has 3 study locations across New York, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.